We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

 

Colon cancer is the third most prevalent cancer for both men and women in the United States. It’s also the second most common cause of cancer-related deaths1—yet no two colon cancer patients, or their treatment needs, are the same. Each patient has an individualized level of risk, making the choice of treatment different for everyone. Part of the treatment decision making process involves understanding the likelihood of the colon cancer returning and how a patient’s condition is managed after surgery.

The Oncotype DX Colon Recurrence Score® test is clinically validated to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers. The 12-gene genomic test (seven cancer-related genes and five reference genes) looks at the underlying biology of a patient’s tumor so patients can choose a treatment that fits their unique situation.